HOHL BENJAMIN (CHIEF FINANCIAL OFFICER) sold 13.7% of their position (6.02K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $303.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 9/21/2026ACC: 0001882764-26-000008
Officer· CHIEF FINANCIAL OFFICER
Since Feb 2026
-6.02K
Net shares
Net seller
$303.0K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
3.98K acquired · 10K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+3.98K
Price / share
$14.85
Trade value
$59.13K
% of position
9.9%
9/17/2026
40.04K→44.02K
Common Stock
Direct
Shares
−3.54K
Price / share
$50.03
Trade value
$176.85K
% of position
8.0%
9/17/2026
44.02K→40.48K
Common Stock
Direct
Shares
−2.19K
Price / share
$50.72
Trade value
$111.27K
% of position
5.4%
9/17/2026
40.48K→38.29K
Common Stock
Direct
Shares
−289.00
Price / share
$51.49
Trade value
$14.88K
% of position
0.8%
9/17/2026
38.29K→38K
Total
Net shares
−2.04K
Net value
-$243.87K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/17/2026 | M · Option Exercise | +3.98K | $14.85 | $59.13K | 9.9% | 40.04K | 44.02K |
| Common Stock Direct | 9/17/2026 | S · Sale | −3.54K | $50.03 | $176.85K | 8.0% | 44.02K | 40.48K |
| Common Stock Direct | 9/17/2026 | S · Sale | −2.19K | $50.72 | $111.27K | 5.4% | 40.48K | 38.29K |
| Common Stock Direct | 9/17/2026 | S · Sale | −289.00 | $51.49 | $14.88K | 0.8% | 38.29K | 38K |
| Total | −2.04K | -$243.87K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
3.98K shares
Shares
−3.98K
Strike price
14.85
Held after
181.02K
Exercisable
—
9/17/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock3.98K shares | 9/17/2026 | M · Option Exercise | −3.98K | 14.85 | — | 181.02K |